Krisy-Ann Thornby

Krisy-Ann Thornby

Auto-generated profile, based on publicly available information

Krisy-Ann Thornby

Professor of Pharmacy Practice, Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, 901 S. Flagler Drive, West Palm Beach. FL 33416

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
JDJohn A. Dougherty
John A. Dougherty
EGErenie Guirguis
Erenie Guirguis
KTKrisy-Ann Thornby
Krisy-Ann Thornby
Objective: To evaluate glucagon-like peptide 1 receptor agonists (GLP-1 RAs), dipeptidyl-peptidase IV (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT) inhibitors to treat nondiabetic and type 2 diabetes mellitus (T2DM) nonalcoholic fatty liver disease (NAFLD) as it relates to improvement in hepatosteatosis (HS) or steatohepatitis (SH). Data Sources: MEDLINE and CINAHL were searched from inception through May 1, 2020. Search terms included nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, fatty liver, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose transporter 2 inhibitors. Study Selection and Data Extraction: Full-text observational and randomized controlled studies in English were included. Patients diagnosed with NAFLD, treated with GLP-1 RAs, DPP-4 inhibitors, and SGLT2 inhibitors, with measures to evaluate HS or SH were evaluated. Data Synthesis: Eight GLP-1 RA trials were reviewed; 7 GLP-1 RA trials showed improvement in HS. Two studies demonstrated improvement in liver histology in patients with SH. Seven SGLT2 inhibitor studies were reviewed; 6 studies demonstrated improvements in NAFLD. Five studies showed improvements in HS, whereas 1 displayed improvement in liver histology in NASH. Six studies that included DPP-4 inhibitors were evaluated, and only 2 demonstrated improvement in NASH. Relevance to Patient Care and Clinical Practice: Based on evidence reviewed, GLP-1 RAs and SGLT2 inhibitors decreased HS and SH in NAFLD patients, whereas DPP-4 inhibitor therapy was not effective for patients with HS. Conclusions: Based on study data utilizing imaging studies and biopsy results, GLP-1 RAs or SGLT2 inhibitors can benefit NAFLD T2DM patients. Clinical trials with larger patient populations may augment these results.

14 July 2021 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
ECElias B. Chahine
Elias B. Chahine
JDJohn A. Dougherty
John A. Dougherty
KTKrisy-Ann Thornby
Krisy-Ann Thornby
EGErenie H. Guirguis
Erenie H. Guirguis
To review the spectrum of activity, efficacy, safety, and role in therapy of all antibiotics and related biologics approved by the Food and Drug Administration (FDA) in the last decade. A literature search was performed using PubMed and Google Scholar (2010 to end May 2021) with the search terms’ name of the antibiotic or the biologic. Data were also obtained from the prescribing information, FDA, and ClinicalTrials.gov websites. All relevant English-language, late phase clinical trials assessing the safety and efficacy of the identified drugs were included. Review articles and references of retrieved articles were evaluated for relevant data. Antibiotic resistance is a public health crisis, and antibiotic development is imperative to outpace the ability of bacteria to develop resistance. Only 17 new systemic antibiotics and 1 related biologic have been approved by the FDA since 2010. Among these drugs, 14 were approved for common bacterial infections, 1 was approved for Clostridioides difficile infection (CDI), 1 was licensed to prevent CDI recurrence, and 2 were approved for drug-resistant tuberculosis. Very few antibiotics are in clinical development. The arrival of these new antibiotics was welcomed with great enthusiasm, particularly when they met previously unmet medical needs. Unfortunately, the majority of them represent modifications to existing chemical structures rather than new drug classes. Despite the availability of these antibiotics, managing patients with deep-seated infections and those with extensively resistant gram-negative organisms remains challenging. The number of new antibiotics and their indications are not keeping up with resistance and the needs of the patients.

29 February 2024 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
DKDenise M. Kolanczyk
Denise M. Kolanczyk
JMJessica R. Merlo
Jessica R. Merlo
BBBridget Bradley
Bridget Bradley
AFAlexander H. Flannery
Alexander H. Flannery
CGCaitlin M. Gibson
Caitlin M. Gibson
KTKrisy‐Ann Thornby
Krisy‐Ann Thornby

26 April 2023 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
KTKrisy-Ann Thornby
Krisy-Ann Thornby
GBGayle A. Brazeau
Gayle A. Brazeau
ACAleda M.H. Chen
Aleda M.H. Chen

17 June 2024 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
EGErenie Guirguis
Erenie Guirguis
JDJohn Dougherty
John Dougherty
KTKrisy Thornby
Krisy Thornby
YGYasmin Grace
Yasmin Grace
KMKeri Mack
Keri Mack
Objective: To review the literature leading to the Food and Drug Administration (FDA) approval of the first medication, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH), including the pharmacology, pharmacokinetics, clinical studies, dosing, and adverse effects. Relevant data will be used to discuss how resmetirom impacts clinical practice. Data sources: A literature search was conducted using MEDLINE from database inception to May 12, 2024. Keywords included non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, and resmetirom. Study selection, data extraction and all English-language studies involving the use of resmetirom for nonalcoholic fatty liver disease (NAFLD)/NASH were included. Data synthesis: Resmetirom, a thyroid hormone receptor agonist, is administered at daily doses of either 80 mg or 100 mg. The drug was shown to provide NASH resolution as assessed by the NAFLD activity score, 80 mg-24.2%, 100 mg-25.9% compared to 14.2% with the placebo group ( P < 0.001). Resmetirom, improved liver fibrosis, 80 mg-25.9%, 100 mg-29.9% compared to 9.7% with the placebo group ( P < 0.001). Resmetirom’s ability to improve fibrosis in patients with F2-F3 fibrosis offers valuable benefit for patients at risk of progressing to cirrhosis. Relevance to patient care and clinical practice: Resmetirom expands the medication options available to treat patients with NASH which can be given alongside other medications to optimize metabolic factors such as glucagon-like peptide-1 and hydroxymethylglutaryl-coenzyme A reductase inhibitors. Resmetirom was well tolerated in studies. Conclusion: Resmetirom serves as an attractive option in patients diagnosed with NASH with evidence of advanced fibrosis (F2-F3) in combination with exercise, diet, and other multimodal therapies targeting metabolic risk factors.

10 March 2015 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
KTKrisy-Ann Thornby
Krisy-Ann Thornby
AHAmy Henneman
Amy Henneman
DBDana A. Brown
Dana A. Brown
Objective: To review the literature evaluating pharmacotherapeutic and nonpharmacotherapeutic options available to reduce migraines or headaches associated with intravenous immunoglobulin (IVIG) treatment. Data Sources: A search of MEDLINE (1946 to February 2015) and other secondary resources was performed using the terms immunoglobulin, immune globulin, intravenous immunoglobulins, migraine , and headache . Other relevant articles referenced from the MEDLINE search were also utilized. Study Selection and Data Extraction: Data sources were limited to English language clinical trials and case studies. In all, 6 clinical studies and 2 case reports met the criteria. Data Synthesis: Headaches or migraines are common adverse effects associated with the administration of IVIG. We evaluated 6 clinical studies and 2 case reports discussing this adverse event in patients treated with IVIG. Strategies used were hydration, switching to an alternate IVIG product, decreased infusion rates, or treating with oral analgesics, opioids, propranolol, sumatriptan, or dihydroergotamines before, during, or after the IVIG infusion. Overall, the majority of patients experienced improvement in headache symptoms, suggesting benefit, after using the various strategies discussed. However, the evidence is limited to case reports and clinical studies with small sample sizes that do not directly measure cause and effect of headache resolution and therapy given in those treated with IVIG. Conclusions: An individualized treatment plan consisting of a pharmacotherapy or nonpharmacotherapy strategy used in the literature should be recommended after careful consideration of the patient’s condition, specific IVIG product used, history of migraine, and previously failed and successful therapies.